Author pages are created from data sourced from our academic publisher partnerships and public sources.
Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
- C. Chapple, L. Cardozo, V. Nitti, E. Siddiqui, M. Michel
- Neurourology and urodynamics
- 1 January 2014
Mirabegron, the first β3‐adrenoceptor agonist to enter clinical practice, has a different mechanism of action from antimuscarinic agents. This review presents data on the efficacy, safety, and… Expand
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
Study Type – Therapy (prevalence)
The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation
- E. Siddiqui, Majid Shabbir, D. Mikhailidis, F. Mumtaz, C. Thompson
- BJU international
- 1 March 2006
To investigate the role of serotonin (5‐hydroxytryptamine, 5HT) and its antagonists in the proliferation of high‐grade bladder cancer cells (HT1376), as high‐grade bladder cancer has a rapid rate of… Expand
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
BACKGROUND Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. … Expand
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a…
Objective: To compare the efficacy and safety of mirabegron 50 mg and solifenacin 5 mg in overactive bladder (OAB) patients dissatisfied with previous antimuscarinic treatment due to lack of… Expand
Cancers of the bladder
- N. Sengupta, E. Siddiqui, F. Mumtaz
- The journal of the Royal Society for the…
- 1 September 2004
Bladder cancer is the fifth most common malignancy in Europe and the fourth most common malignancy in the United States.1 It affects one in 4000 people and accounts for 5% of all diagnosed cancers.… Expand
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
CONTEXT Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as ﬁrst-line pharmacologic therapy. Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment… Expand
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised…
BACKGROUND Incontinence has a greater detrimental effect on quality of life than other symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic monotherapy. … Expand
The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
INTRODUCTION mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of… Expand
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics
- A. Wagg, V. Nitti, C. Kelleher, D. Castro-Díaz, E. Siddiqui, T. Berner
- Current medical research and opinion
- 17 February 2016
Abstract Objective Overactive bladder (OAB) is a particular challenge to treat in older adults with co-morbid conditions taking multiple medications. Antimuscarinics (e.g., solifenacin, fesoterodine)… Expand